This clinical trial is focused on studying Cushing’s disease, a condition where the body produces too much of a hormone called cortisol. The study involves a medication called osilodrostat, also known by its code name LCI699. Osilodrostat is available in the form of film-coated tablets, with doses of 1 mg, 5 mg, and 10 mg. The purpose of the study is to understand how osilodrostat is processed in the body and how well it is tolerated by children and adolescents aged 6 to under 18 years who have Cushing’s disease.

Participants in the study will take osilodrostat orally, meaning they will swallow the tablets. The study will last for a period of up to 48 weeks. During this time, researchers will monitor how the medication affects the levels of cortisol in the body and assess any side effects. The study aims to gather information on the safety and effectiveness of osilodrostat in managing Cushing’s disease in young patients.

Throughout the study, participants will have regular check-ups to track their progress and ensure their well-being. The study will help determine if osilodrostat can be a suitable treatment option for children and adolescents with Cushing’s disease, especially for those who have not had success with surgery or are waiting for surgery. The findings from this study could provide valuable insights into managing this condition in younger patients.